Informed by the metabolic plasticity observed upon FGFR inhibition in FGFR2 fusion+ ICC cells, we next explored the potential of targeting emerging metabolic vulnerabilities to improve treatment efficacy. Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.